科研之友
微信
新浪微博
Facebook
分享链接
摘要
OBJECTIVE: Neoadjuvant chemotherapy(NAC) is a standard treatment option for locally advanced breast cancer.However,there are still lack of efficient methods to predict treatment response before neoadjuvant chemotherapy.Several reports have suggested that lymphocyte-monocyte ratio is associated with prognosis in some tumors.In this study,we evaluated the predictive value of lymphocyte-monocyte ratio(LMR) for chemosensitivity in breast cancer patients who received NAC.METHODS: We analyzed the clinical data of 55 breast cancer patients with NAC in the Affiliated Hospital of Southwest Medical University from January 31,2018 to March 8,2019,Cutoff values of LMR were estimated by Yoden index,and the patients were divided into high or low ratio group according to cutoff values.The response to neoadjuvant chemotherapy was evaluated using the histopathological criteria for assessment of therapeutic response in breast cancer.The relation between LMR and response to neoadjuvant chemotherapy was analyzed.RESULTS: Patients with a higher LMR(≥4.87) were more likely to achieve a better response to neoadjuvant chemotherapy than those with a lower LMR (<4.87; 90.6% vs 43.5%; χ2=14.420,P<0.001).The LMR,but not tumor size (χ2=0.007,P=0.931),lymph node status (χ2=2.208,P=0.154),histologic grade (χ2=0.931,P=0.335),clinical stage (χ2=0.026,P=0.871),molecular types (χ2=5.519,P=0.063),or Ki-67 index (χ2=0.004,P=0.953),was correlated with response to neoadjuvant chemotherapy.Multivariate logistic regression analysis showed that high LMR was an independent predict factor in breast cancer patients with NAC (OR:0.073,95%CI:0.016-0.333,P=0.001).CONCLUSION: High LMR in peripheral blood of breast cancer patients may achieve better response to neoadjuvant chemotherapy than those exhibiting lower LMR.
